Toxic Epidermal Necrolysis Induced by Allopurinol, One Case in a Million
Main Article Content
Abstract
Background:Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are part of the spectrum of one of the most serious dermatological conditions that occur in the hospital setting, considered a dermatological emergency. Stevens-Johnson syndrome is called toxic epidermal necrolysis (TEN) when ≥30% of the body surface is affected, and it is the most serious form of the disease, with adverse drug reactions being the main etiology, up to 80%.
Clinical case:We present the clinical case of a 30-year-old male, with a history of systemic arterial hypertension, who began with symptoms after taking allopurinol after being diagnosed with hyperuricemia. It began with a picture of bilateral conjunctivitis, followed by a sudden appearance of localized dermatosis on the face, characterized by erythematous plaques with indistinct, non-painful borders, and later the appearance of ulcers and blisters, extending to 70% of the body surface. During his hospitalization, he developed a lesion acute renal failure, managed by the intensive care service, with total remission upon discharge and favorable response to treatment thanks to multidisciplinary management. Treatment was provided with human immunoglobulin, vancomycin-based antibiotic therapy, and ciprofloxacin for impetiginization of facial ulcers, fluid therapy, Vaseline gauze dressings, and topical ophthalmological treatment, achieving discharge without comorbidities.
Conclusion:Toxic epidermal necrolysis is a severe picture of Steven Johnson Syndrome, potentially fatal, which requires early multidisciplinary management that leads to the recognition and management of associated comorbidities in a timely manner.Key words: Stevens-Johnson syndrome; toxic epidermal necrolysis; halopurinol, drug reaction.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
I. Schneider, JA, Cohen, PR . Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Concise Review with a Comprehensive Summary of Therapeutic Interventions Enfatizizing Supportive Measures. Adv Ther 34 , 1235–1244 (2017). https://doi-org.pbidi.unam.mx:2443/10.1007/s12325-017-0530-y
II. P. Wolkenstein, YT Wilson, Toxic epidermal necrolysis: the past, the guidelines and challenges for the future Journal of Dermatology , volumen 174, número 6, 1 de junio de 2016, páginas 1171–1173, https://doi.org/ 10.1111/bjd.14682
III. Dodiuk-Gad RP, Chung WH, Valeyrie-Allanore L, Shear NH. Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: An Update. Am J Clin Dermatol. 2015 Dec;16(6):475-93. http://doi:10.1007/s40257-015-0158-0. PMID: 26481651.
IV. Creamer D, Walsh SA, Dziewulski P, Exton LS, et al. UK guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis in adults 2016. J Plast Reconstr Aesthet Surg. 2016 Jun;69(6):e119-e153. doi: 10.1016/j.bjps.2016.01.034. PMID: 27287213.
V. Ingen-Housz-Oro, S., Duong, TA., Bensaid, B. et al. Epidermal necrolysis French national diagnosis and care protocol (PNDS; protocole national de diagnostic et de soins). Orphanet J Rare Dis 13, 56 (2018). https://doi.org/10.1186/s13023-018-0793-7
VI. Haur Yueh Lee, Wound management strategies in Stevens-Johnson syndrome/toxic epidermal necrolysis: An unmet need, Journal of the American Academy of Dermatology, Volume 79, Issue 4, 2018,Pages e87-e88,ISSN 0190-9622, https://doi.org/10.1016/j.jaad.2018.05.1258.
VII. Meregildo-Rodríguez ED, Asmat-Rubio MG, Sánchez-Carrillo HC, Chavarri-Troncoso FP. Necrólisis epidérmica tóxica secundaria a la administración concomitante de lamotrigina, ácido valproico y fenobarbital. Dermatol Rev Mex 2022; 66 (1): 108-116.
https://doi.org/10.24245/dermatolrevmex.v66i1.7439
VIII. Frederick W. Endorf, MD, Leopoldo C. Cancio, MD, Nicole S. Gibran, MD, Toxic Epidermal Necrolysis Clinical Guidelines, , Journal of Burn Care & Research , volumen 29, número 5, septiembre-octubre de 2008, páginas 706–712. https://doi.org/10.1097/BCR.0b013e3181848bb1
IX. YK Heng, HY Lee, J.‐C. Roujeau Epidermal necrolysis: 60 years of errors and advances, British Journal of Dermatology , volumen 173, número 5, 1 de noviembre de 2015, páginas 1250–1254, https://doi.org/10.1111/bjd.13989
X. Diagnóstico y Tratamiento de la Estomatitis Aftosa recurrente México: Instituto Mexicano del Seguro Social 2011, Fecha de acceso 26.03.23 en: http://www.imss.gob.mx/profesionales/guiasclinicas/Pages/guias.aspx
XI. C.A. Barrera-Ochoa, Use of Intravenous Immunoglobulins and Systemic Corticosteroids in Patients With Toxic Epidermal Necrolysis: Experience of a Hospital in Mexico City, Actas Dermosifiliogr. 2022;113:T294-T29910.1016/j.ad.2022.02.021
XII. Martínez-Cabriales SA, Gómez-Flores M, Ocampo-Candiani J. Actualidades en farmacodermias severas: síndrome de Stevens-Johnson (SSJ) y necrólisis epidérmica tóxica (NET) [News in severe clinical adverse drug reactions: Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN)]. Gac Med Mex. 2015 Nov-Dec;151(6):777-87. Spanish. PMID: 26581536.
XIII. Oakley AM, Krishnamurthy K. Stevens-Johnson Syndrome. 2023 Apr 10. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan–. PMID: 29083827.
XIV. Hasegawa A, Abe R. Recent advances in managing and understanding Stevens-Johnson syndrome and toxic epidermal necrolysis. F1000Res. 2020 Jun 16;9:F1000 Faculty Rev-612. PMID: 32595945; PMCID: PMC7308994. doi: 10.12688/f1000research.24748.1.
XV. Hasegawa A, Abe R. Recent advances in managing and understanding Stevens-Johnson syndrome and toxic epidermal necrolysis. F1000Res. 2020 Jun 16;9:F1000 Faculty Rev-612. doi: 10.12688/f1000research.24748.1. PMID: 32595945; PMCID: PMC7308994.
doi:10.1186/1750-1172-5-39
XVI. Aihara M, Kano Y, Fujita H et al. Efficacy of additional i.v. immunoglobulin to steroid therapy in Stevens-Johnson síndrome and toxic epidermal necrolysis. J Dermatol 2015; 42:768–77.https://doi.org/10.1111/1346-8138.12925
XVII. Salazar MJ, Valverde JA, Agüero SAC. Síndrome de Stevens-Johnson y Necrólisis Epidérmica Tóxica, un reto diagnóstico y terapéutico . Revista Médica Sinergia. 2020;5(01):308. https://www.medigraphic.com/cgibin/new/resumen.cgi?IDARTICULO=90638